Uterine fibroids are the most common benign gynecologic tumor in women, with approximately 30% of women suffering from them. The full name for fibroids is smooth muscle tumor of the uterus, which is composed of the same tissue as the uterus itself. Uterine fibroids are called subplasmic fibroids, intermural fibroids, and submucosal fibroids, depending on their location in the uterus. If multiple fibroids are present, they are called multiple fibroids. The cause of fibroids is not clear, but one thing is clear: it is related to estrogen levels. It develops mostly in women of childbearing age. Fibroids are rare before puberty and gradually shrink after menopause. If the fibroids are less than 5 cm, asymptomatic near menopause can be observed, but a very small percentage of them suddenly increase in size at this time, which may be a malignant change of fibroids. Therefore, observation is necessary. Women who have not yet had children should be aware that fibroids may recur after surgery and that postoperative adhesions may affect pregnancy. It is better to operate after childbirth. Surgery is also possible if the fibroids are too large or located in such a way that they may affect fertility, but it is important to fully evaluate before surgery whether the results are reliable. Due to the profit-driven blind expansion of beds in some hospitals, the utilization rate of beds decreases, and some doctors admit patients with fibroids for surgery regardless of whether they are surgical indications. Therefore, patients suffering from uterine fibroids should be diagnosed in one hospital and then it is better to go to another regular hospital for another examination. Before deciding on any treatment, especially invasive treatment and high-priced treatment be consulted in many ways. Be cautious about new technologies, as any new technology should be validated by clinical trials. New advances Eulercept acetate is a selective progesterone receptor modulator (SPRM) that potently modulates progesterone receptor activity while exerting an apoptotic/anti-proliferative effect on fibroblasts. Previous clinical trials have shown that short-term (3 months) use of UPA can reduce menstrual flow and shrink fibroid volume, with menstruation returning within 4-5 weeks and fibroid volume reduction being maintained for 6 months after the end of treatment.